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Myostatin is a powerful negative regulator of skeletal muscle mass in
mammalian species. It plays a key role in skeletal muscle homeostasis and
has now been well described since its discovery. Myostatin is capable of
inducing muscle atrophy via its inhibition of myoblast proliferation,
increasing ubiquitin-proteasomal activity and downregulating activity of
the IGF–Akt pathway. These well-recognized effects are seen in multiple
atrophy causing situations, including injury, diseases such as cachexia, dis-
use and space flight, demonstrating the importance of the myostatin signal-
ling mechanism. Based on this central role, significant work has been
pursued to inhibit myostatin’s actions in vivo. Importantly, several new
studies have uncovered roles for myostatin distinct from skeletal muscle
size. Myostatin has been suggested to play a role in cardiomyocyte homeo-
stasis, glucose metabolism and adipocyte proliferation, all of which are
examined in detail below. Based on these effects, myostatin inhibition has
potential to be widely utilized in many Western diseases such as chronic
obstructive pulmonary disease, type II diabetes and obesity. However, if
myostatin inhibitors are to successfully translate from bench-top to bedside
in the near future, awareness must be raised on these non-traditional
effects of myostatin away from skeletal muscle. Indeed, further research
into these novel areas is required.
Keywords adipogenesis, cachexia, cardiomyocyte homeostasis, glycolysis,
muscle atrophy.
Introduction
More than a decade has passed since the initial identi-
fication of myostatin by McPherron et al. (1997), but
the area still receives a significant amount of attention;
new publications continue to emerge in both tradi-
tional and unexpected fields, demonstrating both the
depth and dynamic nature of this field. The impor-
tance of myostatin is well established in regulating
skeletal muscle homeostasis in a wide variety of condi-
tions (e.g. Gonzalez-Cadavid et al. 1998, Gonzalez-
Cadavid & Bhasin 2004, Costelli et al. 2008), as we
will discuss in the following sections. Indeed, it is the
powerful role of myostatin in the regulation of the
size of muscle mass that has resulted in it receiving so
much initial attention. To the best of the authors’
knowledge, every situation where muscle mass levels
are altered is coupled with published examples of
alterations in myostatin levels either systemically or at
the tissue level.
Where various stimuli of a different nature lead to
a similar phenotypic effect, it is plausible to hypothe-
size a ‘bottleneck’ in inter- or intracellular signalling
must exist at some level. Understanding the common
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mechanisms involved during all types of muscle mass
loss is necessary and will result in future work to
develop treatments targeting this hypothetical bottle-
neck. If a common pathway in signalling can be iden-
tified and targeted, it would prove beneficial in a wide
variety of conditions, both pathological and environ-
mental, in the prevention of muscle atrophy, as seen
during disuse, space flight, injury, disease, cachexia
and ageing. As reviewed below, increased myostatin
expression is seen in all these homeostatic perturba-
tions; however, the key question to be answered is of
cause and effect. Does myostatin cause muscle mass
alterations or is it altered in response? Throughout
this review, evidence will be presented to support the
working hypothesis that myostatin represents a central
regulating factor in alterations in skeletal muscle
homeostasis by multiple mechanisms.
Further, recent findings have hinted that myostatin
may perform more diverse roles away from its tradi-
tional control over the size of skeletal muscle mass;
suggesting exciting new research directions and appli-
cations may emerge in the future. Specifically, evi-
dence has been presented for myostatin signalling
playing a significant role in the regulation of glycolysis
(Chen et al. 2010), adipogenesis (Feldman et al. 2006)
and cardiomyocyte homeostasis (Bish et al. 2010), all
significant in modern ‘Western diseases’ such as type
II diabetes, cachexia and heart disease. As is often the
case with early exciting findings, the picture emerging
is more complex than originally thought. As we move
forward towards the use of myostatin inhibitors in
clinical settings, an understanding of the role of myo-
statin in these non-traditional sites of action will help
shape understanding of potential negative side effects
that future treatments may otherwise unexpectedly
present with, as well as shape novel areas of transla-
tional research.
Here, we briefly review the initial 10 years of
research into myostatin with the aim of introducing
the non-muscle physiologist to the depth and breadth
of research surrounding myostatin before discussing
emerging findings, and finally, we will discuss possible
future directions. Throughout this review, the use of
the term ‘muscle’ should be considered to refer to
skeletal muscle, unless otherwise noted. Furthermore,
unless otherwise noted, ‘myostatin’ is in reference to
the bioactive C-terminus peptide.
The first decade
Myostatin (originally named growth and differentia-
tion factor-8; GDF-8) is a member of the GDF family,
a subgroup of the transforming growth factor b family
of proteins. Myostatin was first characterized by
McPherron et al. (1997), while generating strains of
GDF negative (/) mice to characterize phenotypic
functions and developmental expression patterns.
Myostatin / mice were noted to be larger than
wild-type mice, with a 30% increase in body mass.
This difference in size was demonstrated to be the
result of significant muscular hypertrophy, with indi-
vidual muscles 200–260% larger than wild-type ani-
mals. Expression of myostatin RNA appeared to be
primarily restricted to muscle tissue, with a small sig-
nal from adipose tissue (McPherron et al. 1997).
The presence of myostatin homologues was identi-
fied by Southern blot analysis in multiple mammalian
species, including humans (McPherron et al. 1997). It
was quickly confirmed that myostatin was relevant in
other mammalian species. Multiple groups simulta-
neously identified that the excessive muscle growth
seen in Belgium Blue cattle was because of a naturally
arising mutation in the myostatin-coding gene (Grobet
et al. 1997, Kambadur et al. 1997, McPherron & Lee
1997). In a similar finding, whippet dogs with exces-
sive muscle growth were found to have a heterozygous
naturally occurring mutation (Mosher et al. 2007).
This finding was interesting that these dogs were well
known by the racing community to have greater exer-
cise performance than wild-type animals, demonstrat-
ing increased muscle mass owing to myostatin
deletion was functional, a finding that has limited par-
allels in humans (Seibert et al. 2001). In an early in-
terventional study, sheep were subjected to reduced
food intake to induce muscle atrophy. Myostatin mus-
cle protein increases mirrored changes in muscle mass,
suggesting some coupling mechanism between myosta-
tin and muscle levels (Jeanplong et al. 2003).
Myostatin also appears in pigs, with detectable
mRNA levels varying both foetally and postnatally,
suggesting a role in development (Ji et al. 1998).
Adult pigs subjected to inflammatory viral infections,
where muscle loss is seen, demonstrate increased myo-
statin expression (Escobar et al. 2004), a result that
creates an interesting causative question. Is myostatin
increased in response to viral inflammation resulting
in muscle atrophy or does viral inflammation cause
muscle mass loss with results in a lower basal myosta-
tin level? This question is addressed in the following
section in detail (New directions – Inflammation).
Myostatin appears to also play a role in fish (Weber
et al. 2005), where upwards of 16 homologues are
noted (Rodgers & Garikipati 2008), occasionally with
roles outside of skeletal muscle (Biga et al. 2004). We
see therefore that the role of myostatin is well main-
tained in mammalian species, with perturbations in
various species coupled with myostatin alterations,
but appears to demonstrate an evolutionary split in
function between mammals and fish, a point noted
previously (Rodgers & Garikipati 2008).
© 2012 The Authors
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Myostatin acts directly upon myocytes; stimulation
of myotubes with recombinant myostatin in vitro
results in decreased myotube diameter (McFarlane
et al. 2006), suggesting a direct catabolic or anti-ana-
bolic effect. Myofibre damage followed by remodel-
ling and increased satellite cell activity is induced by
the snake venom notexin. Injection of notexin in rats
was shown to increase myostatin protein levels during
the 5 days post-remodelling period, returning to base-
line after 7 days (Mendler et al. 2000). In a similar
histological study, myostatin was located in necrotic
fibres after injury by notexin (Kirk et al. 2000). Taken
together, these data suggest myostatin is involved in
the remodelling process from start to finish, first as a
step in the induction of necrosis, then in the promo-
tion of new fibre formation during fibre replacement.
Further, identified increases in myostatin mRNA with
muscle mass loss induced by both burn injury and
dexamethasone injection in rats parallel loss of muscle
mass (Lang et al. 2001, Salehian et al. 2006), the
effects of which are partially inhibited by glutamine
injection (Salehian et al. 2006). Dexamethasone has
similar effects in C2C12 cells, increasing myostatin
protein expression and reducing myotube diameter
(Artaza et al. 2002).
Interesting links exist between models of human
disease and myostatin, suggesting the involvement of
myostatin in cachexic muscle loss. While chronic alco-
hol consumption alone does not appear to increase
muscle myostatin mRNA levels (Molina et al. 2006),
a rat model of liver cirrhosis shows decreases in intra-
muscular myosin heavy chain and MyoD expression
as well as increased myostatin protein levels in sam-
ples taken from gastrocnemius (Dasarathy et al.
2004). Serum myostatin increases coupled with skele-
tal muscle atrophy is also seen in a mouse model of
Addison’s disease (Hosoyama et al. 2005). Chronic
hypoxic exposure in rats, as a model of chronic
obstructive pulmonary disease (COPD), results in ele-
vated myostatin protein levels as well as reduced body
and individual muscle mass, the effect of which is
maintained under pair feeding conditions (Hayot et al.
2010). In mice challenged with implanted tumour
masses, cachexia results along with increases in myost-
atin protein levels at 7 days post-tumour implantation
(Costelli et al. 2008), suggesting myostatin may play a
causative role in cachexic loss of muscle mass.
Another example of variation in musculation is the
sexual dysmorphism seen in mammalian species. Dif-
ferences in expression of myostatin protein levels in
male and female mice post-puberty mirror the differ-
ences in muscle mass seen, with wild-type (+/+) male
mice showing significant body and muscle mass differ-
ences over females post-puberty, as well as decreased
myostatin expression (McMahon et al. 2003a, Old-
ham et al. 2009), suggesting myostatin could be play-
ing a causal role in sexual dysmorphism. Interestingly,
myostatin / mice show opposite dysmorphic mus-
cular hypertrophy, with female muscle mass showing
the greatest pubic increases (Gentry et al. 2010), dem-
onstrating that removing myostatin reduces (but does
not remove) sexual dysmorphic differences. Interest-
ingly, the findings of Oldham et al. (2009) demon-
strated the inhibitory effects of myostatin were caused
by altered myostatin levels, not altering inhibitory
propeptide levels. Alternatively, in elderly humans,
males demonstrate higher concentrations of myostatin
protein than females (Gruson et al. 2011). However,
while Oldham et al. (2009) utilized Western blot,
Gruson et al. (2011) used an immunoassay that recog-
nizes both the mature peptide and the inhibitory pro-
peptide, potentially confounding results.
Human findings
The first report suggesting myostatin may be playing a
role in human muscle homeostasis came from Gonz-
alez-Cadavid et al. (1998) who demonstrated a nega-
tive correlation between serum myostatin levels and
muscle mass in healthy individuals as well as those
with HIV, both with and without cachexia. Myostatin
elevation in response to chronic disorders is also seen
in COPD (Hayot et al. 2010).
It was also demonstrated that 25 days of ‘head
down’ bed rest, commonly used to model the physio-
logical effect of microgravity, resulted in significant
loss of lean body mass and serum myostatin concen-
trations that were significantly elevated by 12% from
baseline (Zachwieja et al. 1999). Negative correlations
were again noted between lean body mass and serum
myostatin concentrations (Zachwieja et al. 1999). In
another model of disuse atrophy, hip arthroplasty is
coupled with increased myostatin mRNA expression
5 days post-surgery (Reardon et al. 2001).
Mixed evidence for myostatin elevations are seen in
sarcopenia with some authors noting no relationship
between myostatin mRNA levels and muscle mass
(Marcell et al. 2001, Ratkevicius et al. 2011), while
others show a correlation between increased circulat-
ing myostatin levels and the level of muscle mass loss
in sarcopenic patients (Schulte & Yarasheski 2001,
Yarasheski et al. 2002, Leger et al. 2008). Indeed, fur-
ther evidence for myostatin playing a role in ageing
are provided by a study in aged mice where myostatin
inhibition results in increased muscle fibre cross-sec-
tional area and grip strength (Siriett et al. 2007).
Interestingly, genetic polymorphisms of myostatin
have been identified in elderly females that parallel
loss of muscle mass (Seibert et al. 2001). If some indi-
viduals are more sensitive to alterations in myostatin
© 2012 The Authors
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expression, then this may help explain this variation
in findings.
With fortuitous timing, a newborn child was identi-
fied in Germany as carrying a myostatin null mutation
after being noted to have an unusually high level of
muscle mass at birth (Schuelke et al. 2004). Besides
increased muscular development, the child developed
physiologically and mentally normally. Subsequent
individuals with similar myostatin deficiencies have
since been identified, however all with various other
genetic mutative disorders (Gonzalez-Freire et al.
2009, Prontera et al. 2009, Meienberg et al. 2010).
The presence of such myostatin / humans confirms
myostatin’s role is maintained.
Resistance exercise is a well-defined stimulus for
muscular hypertrophy (Kraemer et al. 2002), and not
surprisingly, is coupled with altered myostatin expres-
sion. Nine weeks of a resistance training designed to
build muscle mass resulted in reduced myostatin
mRNA in muscle (Roth et al. 2003) and 10 weeks of
a similar programme resulted in decreased serum myo-
statin (Walker et al. 2004). In contrast, Willoughby
showed increases in both muscle mRNA and serum
protein levels of myostatin after 12 weeks of resis-
tance training (Willoughby 2004a,b). This increase
may have been because of timing of sampling, as Wil-
loughby (2004a,b) took samples immediately post the
final training session, whereas Walker et al. (2004)
waited 2 days post the final session to ensure a basal
level was examined. Indeed, the acute response to a
single bout of isometric exercise in rats demonstrates
a rapid increase in myostatin mRNA levels 30 min to
6 h post-exercise, returning to baseline levels 24 h
post-exercise (Peters et al. 2003), a finding that has
yet to be paralleled in experiments on human partici-
pants. Furthermore, after 2 weeks cast immobilization
significant myostatin mRNA decreases 24 h and
6 weeks post-return to mobility are seen (Jones et al.
2004) and 21 weeks of resistance training results in
reduced myostatin mRNA expression 48 h post the
final training session (Table 1; Hulmi et al. 2007).
Different resistance training protocols have been
shown to have different effects on myostatin levels
(Heinemeier et al. 2007), perhaps unsurprisingly, as it
is recognized that muscle-building exercise is a com-
plex, often oversimplified task (Kraemer et al. 2002).
Indeed, it would appear that the effect of resistance
exercise is dose-dependent as light resistance exercise
(20% 1RM, four sets, 15–30 reps) does not alter
mRNA myostatin levels in healthy, untrained males
and females (Manini et al. 2011).
Taken together, these data suggest resistance exer-
cise may induce an acute increase in myostatin activity
to promote cellular remodelling (Peters et al. 2003,
Willoughby 2004b), followed by a chronic adaptive
response of decreased basal expression (Hulmi et al.
2007), facilitating a hypertrophic phenotype. To the
best of the author’s knowledge, no acute time course
of myostatin expression post-resistance training has
been completed.
The effect of endurance exercise on myostatin is less
well defined in human studies. Six months of endur-
ance exercise training decreases serum and muscle
myostatin protein levels in middle-aged men (Hittel
et al. 2010), and 9 weeks of endurance exercise
decreases muscle myostatin mRNA levels in mainte-
nance haemodialysis patients (Kopple et al. 2006).
The response of muscle myostatin mRNA varies by
trained state; endurance-trained cyclists show a small
decrease in muscle myostatin mRNA three hours after
maximal resistance training, while resistance-trained
power lifters show no changes (Coffey et al. 2006).
Unfortunately, this study did not directly compare
between resistance- and endurance-trained athletes at
baseline, which would have made for an interesting
comparison.
If animal work in endurance training is examined in
lieu of human findings, we see that chronic endurance
Table 1 Effect of resistance training on serum myostatin levels
Sessions
per week





effect % Increase Measured
Willoughby
(2004b)
3 9 12 3 9 6–8 (85–90%)
3 9 10–12 weeks 1–3 (80%)




2 9 10 4 9 8–10 weeks 4–6
4 9 6–8 weeks 7–10
48 h post ↓↓↓ 20% Protein
Jones et al.
(2004)
3 9 6 Resumption of weight
bearing following disuse
48 h post ↓↓↓ 48% mRNA
Hulmi et al.
(2007)
2 9 21 5 9 10 (at 10RM) 48 h post ↓↓↓ 48% mRNA
↑↑↑indicates an increase in myostatin level; ↓↓↓ indicates a decrease.
© 2012 The Authors
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training in rats induces a decrease in muscular myost-
atin mRNA, while a single acute bout does not
(Matsakas et al. 2006). Counter to this, 14 days vol-
untary running wheel activity (>4000 m day1) has
no effect on muscle myostatin mRNA expression in
rats (Bodell et al. 2009), nor does 5 weeks of tread-
mill running (1 h day1, 21 m min1) in mice (Lehti
et al. 2007). A potential hypothesis explaining this
difference would be exercise modality. Matsakas et al.
(2006) utilized swim training, which has been shown
to have varying effects on fibre-type conversion and
enzymatic expression when directly compared to
wheel running in mice (Matsakas et al. 2010).
While acute starvation (40 h) does not appear to
alter myostatin expression, either in serum or from
muscle biopsy (Larsen et al. 2006), 18 months post-
biliopancreatic diversion surgery in morbidly obese
individuals does demonstrate a decrease in myostatin
mRNA expression from muscle biopsy (Milan et al.
2004). The result of Larsen et al. (2006) is perhaps
unsurprising as no alterations were seen in any of the
measured pathways of either catabolism (atrogin,
murf) or synthesis (IGF-1), suggesting perhaps the
timeline investigated was insufficient to induce a
response. It also should be noted that the subject pool
used in the study by Larsen et al. (2006) was small
(N = 6, 3 = ♂, 3 = ♀).
Mechanisms of actions
With the rapid build-up of knowledge outlining the
importance of myostatin in the regulation of skeletal
muscle with various atrophic and hypertrophic stim-
uli, the key research direction was to understand how
myostatin-controlled muscle homeostasis, as the abil-
ity to mediate such a powerful regulator, would have
clear clinical benefits in a wide variety of conditions.
Myostatin is expressed primarily by myotubes
in vitro, where it is primarily found in the nucleus
(Artaza et al. 2002). As noted earlier, myostatin cir-
culates as an endocrine hormone and can be mea-
sured in serum, with serum levels correlating with
muscle mass in healthy and cachexic HIV patients
(Gonzalez-Cadavid et al. 1998). Upon atrophic stim-
ulation of mature myotubes by dexamethasone, myo-
statin is released into the cytoplasm of the cell
(Artaza et al. 2002). After propeptide cleavage, the
active C-terminus of myostatin forms a homodimer
under normal conditions (Taylor et al. 2001). Myost-
atin is then held in an inactive state by its propeptide
(Hill et al. 2003, Jiang et al. 2004). Myostatin can
then be released from the cell (Artaza et al. 2002)
and act in an autocrine or paracrine manner.
Myostatin binds to its receptor, the transmembrane
receptor protein activin receptor type IIB (ARIIB), and
also shares limited binding with activin receptor II
(Rebbapragada et al. 2003). Upon myostatin binding,
ARIIB homodimerizes with either activin receptor-like
kinase-4 or -5 to induce signalling in the internal cel-
lular environment. The role of myostatin appears to
be greater in type II (fast) fibres, as perturbation of
C2C12 cells with dexamethasone induces increases in
myostatin expression to a greater level in cells that
also stain positive for myosin heavy chain type two
(Artaza et al. 2002). Indeed, myostatin expression is
primarily localized in type II ‘fast twitch’ cells
(McPherron & Lee 1997, Allen & Unterman 2007).
Further, the hypertrophy seen with myostatin /
mice is greatest in type II muscle fibres (McPherron
et al. 1997, personal obervations), and inhibition of
myostatin activity results in greater hypertrophy in
type II fibres over type I (Lawlor et al. 2011). Finally,
murine type II muscle appears to have greater expres-
sion of ACTRIIB mRNA (Allen & Unterman 2007),
providing a further explanation for the above-men-
tioned findings.
An early hypothesis was for a direct link between
growth hormone (GH) and myostatin. Indeed, Liu
et al. (2003) noted GH addition to C2C12 cells
resulted in decreased myostatin expression, and inhibi-
tion of GH had the opposite effect. However, treat-
ment of pigs with GH does not appear to change
muscle myostatin level (Ji et al. 1998). Treatment of
GH-deficient adults with GH does reduce myostatin
mRNA expression, but not the bioactive protein levels
(Liu et al. 2003). Furthermore, the myostatin response
to muscle overload in adult hypophysectomized rats is
not altered (Yamaguchi et al. 2006), suggesting the
relationship seen by Liu et al. (2003) was indirect in
nature.
Loss of muscle mass in vivo may either be as a
result of inhibition of synthesis, an increase in degra-
dation or some combination of the two. Myostatin
activity appears to inhibit the Akt-mTOR pathway,
upregulate activity of the ubiquitin-proteasomal mech-
anism and prevent synthesis by inhibition of satellite
cell replication and translocation, examined separately
below.
Myostatin & satellite cell activity
As myotubes are both multinucleated and terminally
differentiated, the only source of new nuclei during
hypertrophy of mature myotubes is fusion of new
myoblasts from satellite cells. It was quickly confirmed
that one mechanism of myostatin was to inhibit myo-
blast proliferation. C2C12 myoblasts cultured in stan-
dard growth media (Dulbecco’s modified Eagle’s
media + 10% foetal bovine serum) in the presence of
myostatin do not replicate, and further, this inhibition
© 2012 The Authors
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of myoblast proliferation is dose-dependent (Thomas
et al. 2000, Taylor et al. 2001). These effects appear
to be via a prevention of Pax7–MyoD co-localization,
maintaining satellite cells in quiescence. Increases
in recombinant myostatin protein levels result in
decreased co-localization, maintaining satellite cells in
quiescence and preventing proliferation (McFarlane
et al. 2008).
Further to the direct effects of myostatin on prolif-
eration, myostatin appears to have the ability to inhi-
bit fusion of myoblasts into differentiated myotubes.
Cloned C2C12 cells overexpressing myostatin have a
reduced differentiation response (Rios et al. 2002),
which appears to result from inhibition of MyoD
activity (Langley et al. 2002). MyoD is a key rate-lim-
iting step in the formation of mature myotubes, it
being necessary for myoblast differentiation (Megeney
et al. 1996). The effect of myostatin on MyoD
appears to be mediated via the common SMAD sig-
nalling pathway, similar to other TGF-b family mem-
bers. Specifically, in response to myostatin binding to
its receptor, SMAD2 and SMAD3 are phosphorylated,
inducing binding with SMAD4, allowing the entire
transcription factor complex to translocate and block
MyoD production (Zhu et al. 2004, Allen & Un-
terman 2007), thereby subsequently reducing the abil-
ity of new myoblasts to proliferate and fuse.
However, it should be noted that the effect of myo-
statin on satellite cell activity may not be a necessary
step in muscular hypertrophy. Myostatin treatment
appears to have no effect on myoblast proliferation in
vitro. Further, myostatin / mice do not show
significantly increased number of satellite cells over
wild-type mice, as measured by Pax7-positive staining
during immunohistochemistry (Amthor et al. 2009).
The authors may have potentially overreached with
the significance of this conclusion however, as their
Pax7 methodology measured only number of satellite
cells but gave no information on the more important
ratio of activation to quiescence. These findings
remind us that the effect of myostatin on muscle mass
is multipathway-dependent, as seen in Figure 1 below.
Finally, once proliferation has taken place, new
myoblasts must fuse to produce mature myotubes.
Myoblasts co-cultured in differentiation media with
myostatin (100 ng mL1) show reduced fusion, the
effect of which is rescued by the inhibition of myosta-
tin (Nozaki et al. 2008).
Increased proteasomal activity
The ubiquitin-proteasomal system is a key pathway
for the identification of proteins for ubiquitination,
either for the rapid targeted removal of signalling pro-
tein or for the normal protein turnover. Cachexic loss
of muscle mass in chronic conditions often coexists
with elevated proteasomal activity and subsequently
increased protein degradation (reviewed by Mitch &
Goldberg 1996). Muscle tissue has at least two spe-
cific ubiquitin ligases downstream of FoxO1, murf
and atrogin, identified by Bodine et al. (2001). Myost-
atin stimulation (10 lg mL1) of C2C12 cells results
in a decrease in myotube diameter by 57%, with up-
regulated atrogin (150% increase above control) but
not murf. Further, myostatin stimulation in the pres-
ence of siRNA for FoxO1 results in no change in atro-
gin expression (McFarlane et al. 2006), demonstrating
the FoxO1-dependent nature of this mechanism. The
myostatin promoter region contains FoxO1 binding
sites, and activation of these by FoxO1 significantly
increases myostatin expression, where blocking of
FoxO1 activity inhibits myostatin production in both
myoblasts and myotubes (Allen & Unterman 2007).
Furthermore, this signalling pathway is independent of
the above-mentioned SMAD signalling pathway,
C2C12 myoblasts with inhibited SMAD signalling
retain normal FoxO1 activity, and vice versa (Allen &
Unterman 2007). This ability of myostatin to regulate
Figure 1 Three separate intracellular
signaling pathways by which myostatin
is known to alter muscle homeostasis.
© 2012 The Authors
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proteasomal activity is also independent of the (below
described) Akt pathway as Akt / mice produce
atrogin and murf normally in response to myostatin
increases (Goncalves et al. 2010).
Inhibited Akt signalling
GH and IGF-1 promote protein synthesis via Akt, a
powerful anabolic signalling nexus (Goncalves et al.
2010). Akt signalling induces muscular hypertrophy by
multiple mechanisms (reviewed by Frost & Lang 2007).
Myostatin reduces phosphorylated levels of Aktthr308 by
25%, as well as reducing phosphorylation ratio of sev-
eral downstream signalling proteins (Amirouche et al.
2009). This mechanism is distinct from the above-men-
tioned SMAD signalling as inhibition of SMAD2 signal-
ling in the presence of increased myostatin does not
prevent Akt inhibition (Yang et al. 2007).
In parallel to the above findings, elderly (70 years
of age) human participants with sarcopenia demon-
strate increased myostatin levels as well as a reduced
Akt phosphorylation/total Akt ratio (Leger et al.
2008). Opposite effects are seen post-resistance exer-
cise, whereby myostatin protein levels from muscle
biopsy are decreased and phosphorylation of Akt and
its downstream pathway constituents is increased
(Mascher et al. 2008).
It was previously hypothesized that FoxO1 and the
Akt pathway shared a direct link by which phosphory-
lation of FoxO1 reduced activation of mTOR and its
downstream 4E-BP1, thereby further reducing protein
synthesis (Southgate et al. 2007). However, it should
be noted that the publication by Southgate et al.
(2007) has been withdrawn, no reason has currently
been given. The current state of understanding of
myostatin’s effect on synthesis, degradation and satel-
lite cell activity is presented in Figure 1.
Inhibition of myostatin
The above-reviewed papers demonstrate the breadth
of situations where myostatin is involved in the pro-
cess of muscle atrophy. With myostatin’s involvement
in such a range of different conditions, an attractive
hypothesis would be that myostatin acts as a central
regulator or common step in the muscle atrophy pro-
cess. Such a hypothesis makes the potential of myosta-
tin inhibitors clinically attractive as they could
conceivably be useful in a wide range of conditions.
Indeed, in patients with COPD, it has been demon-
strated that peripheral muscle function correlates with
disease progression (Bernard et al. 1998) as well as
with quality of life and mortality (Swallow et al.
2007). If myostatin inhibition could slow or even pre-
vent loss of muscle mass in cachexic and sarcopenic
populations, both quality of life and mortality would
logically be expected to improve.
After propeptide cleavage, the active C-terminus of
myostatin forms a homodimer under normal condi-
tions (Taylor et al. 2001). The myostatin protein is
then held in an inactive state by its propeptide (Hill
et al. 2003, Jiang et al. 2004). As expected, overex-
pression of the myostatin propeptide in vitro leads to
inhibition of myostatin activity (Thies et al. 2001).
Titan-cap, a sarcomeric protein, is also capable of
binding to and inactivating mature myostatin inside
the cell, providing a mechanism of regulating myosta-
tin activity prior to secretion (Nicholas et al. 2002).
As myostatin circulates as an endocrine hormone
(Gonzalez-Cadavid et al. 1998, Zachwieja et al. 1999,
Zimmers et al. 2002), an obvious target would be the
removal of, or nullifying, serum myostatin. Indeed,
GASP-1 (Hill et al. 2003), Follistatin-related gene
(Hill et al. 2002) and follistatin (Zhu et al. 2004) all
circulate systematically and bind to and inhibit myost-
atin activity. Unfortunately, the majority of these
myostatin inhibitors act via multiple mechanisms,
making them unsuited for use. For example, trans-
genic inhibition of follistatin causes perinatal death in
mice and has significant phenotypic effects beyond
muscle mass, as follistatin acts on several aspects of
homeostasis via its effects on the activin family (Mat-
zuk et al. 1995). It is worth noting that follistatin
overexpression in myostatin / mice results in fur-
ther increases in muscle mass over myostatin /
mice alone (Lee 2007), which may be via the effects
of follistatin on other TGF-b family members. Naka-
tani et al. (2008) successfully inhibiting myostatin
expression in a mouse model of muscular dystrophy
(MDX) with a transgenic derivative of follistatin, FS-
1, which maintained its myostatin binding ability but
had reduced activin binding activity. Subsequent FS-1-
overexpressing mice had significantly increased muscle
mass and an increase in individual muscle fibre size
with no reported side effects. FS-1 mice also demon-
strated increased strength and endurance (Nakatani
et al. 2008), showing induced muscular hypertrophy
was functional.
Inhibition of myostatin by serum circulating anti-
body in the MDX mice (a model of muscular dystro-
phy) results in increased muscle mass, enhanced grip
strength and exercise performance, an increase in
basal metabolic rate, but also an increase in the num-
ber of centrally located nuclei in skeletal muscle cells
(Bogdanovich et al. 2002). This increase can either be
interpreted as a sign of abnormal development or a
higher rate of cellular turnover, suggesting more inves-
tigation is necessary. Counter to this, MDX myostatin
/ mice demonstrate no increase in centrally located
nuclei at 15 months of age (Amthor et al. 2009).
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Potentially explaining differences in findings are the
different models used by either group. A constitutive
MDX myostatin / mice is arguably less physiologi-
cally relevant as a research model than an MDX
mouse model treated with a pharmacological myosta-
tin inhibitor.
Whittemore et al. (2003) treated adult mice with an
anti-myostatin monoclonal antibody to assess the
effects of myostatin modulation in the adult animal.
Results demonstrated increased muscle mass, increased
muscle fibre cross-sectional area and importantly,
increased functionality, as measured by grip strength.
Finally, in a mouse model of limb-girdle muscular dys-
trophy, overexpression of a modified, serum-soluble,
myostatin receptor prevented muscle atrophy, appar-
ently via the SMAD signalling pathway, as it was
noted that dystrophic mice had increased SMAD2
activity, whereby treated mice had levels similar to
wild-type mice (Ohsawa et al. 2006). Inhibition of
myostatin during disuse atrophy in mice leads to a
protective effect, partially preventing muscle mass loss
and offsetting loss of force production (Murphy et al.
2011), a finding with exciting applications in settings
such as disuse atrophy and microgravity exposure.
Unfortunately, successful inhibition of myostatin in
human work has yet to be conclusively demonstrated.
Myostatin inhibition utilizing a human analogue of
Whittemore’s work (Whittemore et al. 2003), in
patients with various muscular dystrophies, gives a
dose-dependent increase in muscle fibre size, but no
changes in patient strength or rate of disease progres-
sion (Wagner et al. 2008). Phenotypically, muscle
mass increases were significant in one disease
subgroup (Becker’s muscular dystrophy), while all
other groups were approaching significance. However,
as the authors note, this trial was not powered to
assess muscle mass increases, instead focussing on
drug safety (Wagner et al. 2008).
Finally, small interfering RNA (siRNA) approaches
have been tested successfully in mice models. Kinouchi
et al. (2008) developed and delivered successfully a
siRNA targeting myostatin intravenously, resulting in
reduced muscle myostatin protein expression and
increased muscle mass. Alternatively, antisense-RNA
interference is also possible, antisense-RNA targeting
myostatin mRNA increases muscle mass in both nor-
mal and cachexic mice (Liu et al. 2008), showing
obvious clinical applications.
While myostatin inhibition may soon prove to be a
positive clinical tool in the prevention of muscle loss
during disuse, cachexia and sarcopenia, a note of cau-
tion should be made. Myostatin / mice lost signifi-
cantly greater muscle mass during hindlimb
suspension disuse atrophy than wild-type mice
(McMahon et al. 2003b), counter to the hypothesized
protective effects of reduced myostatin levels. Further,
it was recently noted that some strains of myostatin
/ mice have increased rates of muscle degeneration
and intramuscular lesion formation, where myostatin
/+ mice did not (Gentry et al. 2010), perhaps sug-
gesting that partial inhibition, such as that which
would be seen with pharmaceutical interventions, may
prove safe. Indeed, to the best of the authors’ knowl-
edge, excluding the results of Bogdanovich et al.
(2002) for the above-mentioned reasons, no reports of
muscle pathology have been seen with in vivo myosta-
tin inhibitory studies.
Role in cachexia & disease states
Is myostatin involved in cachexic loss of muscle mass?
The answer must be considered to be yes. Since the
identification of myostatin as muscle-specific regula-
tor, increased myostatin expression has repeatedly
been seen in cachexic patients secondary to HIV/
AIDS, in cancer modelled in mice (Liu et al. 2008)
and rats (Costelli et al. 2008), as well as in humans
with severe COPD (Hayot et al. 2010) and heart fail-
ure (Gruson et al. 2011).
While it is clear that myostatin is involved in the
cachexic loss of muscle mass in human diseases (Gonz-
alez-Cadavid et al. 1998, Hayot et al. 2010, Gruson
et al. 2011), the more important question must be,
‘are changes in myostatin observed during cachexia
causative or secondary to muscle atrophy?’. The
answer to this is less clear and difficult to investigate
in humans. However, there is some evidence to suggest
that myostatin is playing a causative role in cachexia.
First, the cause of cachexia itself is still unclear. A
review by Wagner (2008) describing cachexia in
patients with COPD presented evidence for various
hypotheses including peripheral tissue hypoxia, sys-
temic inflammation and hormonal imbalance poten-
tially involving myostatin and elevated proteasomal
activity. Indeed, the case for systemic inflammation is
a strong one, as increased pro-inflammatory signalling
induced by chronic disease clearly leads to cachexia-
like atrophy in animal models of disease. Interleukin 6
overexpression in mice results in reduced muscle mass
levels (Franckhauser et al. 2008). TNF-a infusion
downregulates IGFBP-5 (Lang et al. 2006), while inhi-
bition of TNF-a prevents inflammatory-induced inhibi-
tion of anabolic Akt pathway members such as
4EBP1, mTOR and ribosomal protein S6 (Lang &
Frost 2007). The transgenic MIKK mouse overex-
presses IjK in a muscle-specific manner, resulting in
constantly activated pro-inflammatory NF-jB activity,
demonstrates significant loss of muscle mass in mice
(Cai et al. 2004). Finally, inhibition of TNF-a par-
tially prevents muscle mass loss in cachexic rats
© 2012 The Authors
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(Steffen et al. 2008). Multiple mechanisms have been
suggested by which increased inflammation results in
increased catabolism, discussed further below (New
directions).
As previously mentioned, serum myostatin protein
levels correlate with muscle mass levels in HIV
patients with and without cachexia, as well as healthy
normal individuals (Gonzalez-Cadavid et al. 1998).
Overexpression of myostatin in mice also directly
leads to muscle wasting in a manner that mirrors
cachexia, both at the cellular level (McFarlane et al.
2006, 2008) and phenotypically (Zimmers et al.
2002). Further, this expression occurs at sites distal to
myostatin expression, demonstrating the endocrine
nature of its actions, as suggested by early work on
human AIDS patients (Gonzalez-Cadavid et al. 1998,
Zachwieja et al. 1999). Finally, muscle atrophy in a
mouse model of cancer cachexia is offset by myostatin
inhibition (Liu et al. 2008).
This hypothesized causative role of myostatin in
cachexia will be confirmed with positive results from
new studies currently utilizing myostatin inhibitors in
animal, and hopefully soon, human clinical studies.
New directions
Inflammation regulation
The myostatin promoter gene expresses a NF-jB bind-
ing site (Ma et al. 2001), suggesting NF-jB is capable
of inducing myostatin transcription. Indeed, concurrent
increases in myostatin expression are seen with viral
pneumonia infection of pigs (Escobar et al. 2004).
Sustained NF-jB activity in mice causes significant
muscle atrophy (Cai et al. 2004). Further, inflamma-
tory mediators such as TNFa act in muscle to inhibit
myogenic differentiation via NF-jB (Guttridge et al.
2000, Li & Reid 2000, Langen et al. 2001, 2004, Li &
Schwartz 2001), upregulate atrogin and murf expres-
sion (Liu et al. 2003, Li et al. 2005), and inhibit the
anabolic actions of the insulin-like growth factor-Akt
pathway (Fernandez-Celemin et al. 2002), all similar
mechanisms to myostatin actions (as reviewed above).
Finally, inhibition of inflammatory processes prevents
the above-mentioned catabolic processes (Costelli et al.
1993, Tessitore et al. 1994, Llovera et al. 1998, Lang
et al. 2006, Lang & Frost 2007).
However, Lang et al. (2001) suggested lipopolysac-
charide (LPS) injection into rats had no effect on myo-
statin, as 24 h post-LPS injection myostatin mRNA
levels were unchanged. Stimulation of cultured myotu-
bes with TNF-a also had no effect on myostatin
mRNA 0.5–24 h post-stimulation (Bakker et al. 2005)
or after 4 days of TNF-a stimulation (Larsen et al.
2008). Finally, attempts to induce NF-jB activity via
myostatin stimulation in C2C12 myoblasts were
unsuccessful (Bakker et al. 2005). Combined, these
results suggest that the hypothesized inflammation–
myostatin link was absent.
Counter to the above findings, increases in myostatin
expression in a rat model of cancer cachexia are offset
with pentoxifylline, an inhibitor of TNF-a (Costelli
et al. 2008). Further, treatment of a rat model of rheu-
matoid arthritis with fenofibrate, to reduce systemic
inflammation, both reduced systemic TNF-a levels and
blunted increases in myostatin, atrogin and murf (Cas-
tillero et al. 2011). One potential explanation for the
discrepancies in these findings may be due to an acute
verses chronic timing model used. While Lang et al.
(2001) investigated 24 h in the rat model, Costelli
et al. (2008) and Castillero et al. (2011) investigated
longer time periods (7 and 15 days, respectively).
To the best of our knowledge, all stimuli resulting
in muscle atrophy involve both increased systemic
inflammation and increased myostatin levels. Indeed,
Frost & Lang (2005) noted that systemic inflamma-
tion by any cause appeared to result in muscle atro-
phy. If a direct myostatin–systemic inflammation link
is confirmed, this link may prove an important link
between inflammation and cachexia, as well as an eas-
ily targetable one. A greater understanding of the
underlying reason behind the discrepancy in findings
is first required.
Adipose activity
Myostatin may play a direct role in the regulation of
adipose homeostasis. Indeed, McPherron et al. (1997)
noted myostatin / mice had detectable myostatin
RNA in adipose. Lin et al. (2002) and McPherron &
Lee (2002) noted that myostatin / mice had signifi-
cantly reduced levels of subcutaneous body fat, with
Lin et al. (2002) further noting that myostatin /
mice showed decreased leptin concentrations. Overex-
pression of the inhibitory myostatin propeptide, reduc-
ing myostatin activity, also results in reduced
subcutaneous adipose tissue (Zhao et al. 2005). Two
possible hypotheses arising could explain this pheno-
type. First, myostatin may act directly on adipocytes,
promoting proliferation or differentiation in a reversed
mechanism as in skeletal muscle. The alternative is
that reduced fat mass may be secondary to increased
metabolic demands of significantly increased muscle
mass of myostatin / mice.
It would seem that the hypothesis for a direct link
between myostatin and adipocytes is more likely as
myostatin has been demonstrated to inhibit differenti-
ation of primary culture of bovine pre-adipocytes
(Hirai et al. 2007). Stolz et al. (2008) directly stimu-
lated adipocytes in vitro with recombinant myostatin
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to further explore this phenomena. Early results
appeared promising, with myostatin regulating SMAD
signalling in a similar manner as muscle, thereby
inhibiting adipogenesis in vitro (Stolz et al. 2008).
However, when Stolz et al. (2008) measured the
effects of myostatin inhibition and overexpression in
mice, findings showed no effect of either intervention
on fat mass. Tissue-specific knockout of myostatin in
muscle and fat reveals that muscle / mice are resis-
tant to weight gain in response to high-fat diets, while
adipose / mice respond to a high-fat diet as normal
(Guo et al. 2009). However, on a chow diet, neither
group has an altered weight gain response when com-
pared to wild-type mice (Guo et al. 2009).
Examining the interaction between myostatin and
adipocytes from the alternative direction, Feldman
et al. (2006) demonstrated that dexamethasone-stimu-
lated adipocytes, in vitro, are capable of producing
and excreting myostatin. Further, this expressed myo-
statin acted in a paracrine manner, directly regulating
the development of the adipocytes in vitro (Feldman
et al. 2006).
Indeed, in vivo adipose tissue appears to alter or uti-
lize myostatin signalling in an endocrine manner. Wild-
type mice fed on a high-fat diet demonstrate elevated
muscle myostatin expression 3, 9 and 12 weeks post
the onset of high-fat intake, which the authors hypothe-
size, may be active in promoting adipogenesis (Lyons
et al. 2010). Post-developmental myostatin / mice
are partially protected from the effects of consuming
high-fat diets, with reduced weight gain, no liver
hypertrophy and reduced intramuscular fat deposits
(Burgess et al. 2011). However, the increase in intra-
abdominal fat deposits after high-fat diet was identical
between wild-type and myostatin / mice (Burgess
et al. 2011). Indeed, transgenic mice overexpressing
myostatin during adipogenesis show resistance to diet-
induced obesity (Feldman et al. 2006), which taken
with the in vitro data above suggest that myostatin
may be a necessary step in the accumulation of fat
mass.
Conversely, myostatin overproduction in adult mice
led to significant decreases in white adipose tissue
(Zimmers et al. 2002). However, it should be noted
that in Zimmers et al. (2002) experiments, myostatin
overexpression was induced by the implantation of
CHO cell tumours overexpressing myostatin, so the
experimental animals had the stimuli of both excess
myostatin and tumour load to enhance catabolism.
When an identical experiment was attempted, but
with excess myostatin provided by injection of recom-
binant protein, no alteration in fat mass was seen
(Stolz et al. 2008).
A picture emerges therefore of myostatin and adi-
pose tissue interaction, whereby increasing adiposity
may upregulate myostatin expression. However, the
role of myostatin overexpression on adipose tissue in
vivo is less clear and warrants further investigation.
There is difficulty in vivo in separating the effects of
myostatin alteration into direct effects on adipocytes
and indirect effects on muscle tissue with then alter
fat mass via alterations of basal metabolic rate.
Indeed, it is possible that the effects seen above are a
result of secondary signalling downstream of myosta-
tin, a point raised previously (Allen et al. 2011). If
increasing adiposity in vivo does stimulate myostatin
overexpression, this could conceivably result in the
reduction of whole body muscle mass, further result-
ing in negative outcome for the obese individual.
Glucose metabolism
Skeletal muscle is the most metabolically demanding
tissue in the human body, being responsible for 20–
30% of energy expenditure at rest and up to 90%
during intense exercise (Zurlo et al. 1990). Stimuli
that alter whole body muscle mass would therefore
have significant effects on substrate utilization, in
terms of both total amount and proportion of fuel
sources.
Increasing muscle mass by myostatin inhibition ele-
vates basal metabolic rate (Bogdanovich et al. 2002)
as would be expected. This has obvious and immedi-
ate clinical applications; treatment of type II diabetics
by myostatin inhibition to altering muscle mass would
hypothetically result in increased whole body energy
consumption, reduce peripheral fat mass and poten-
tially lower blood glucose. Indeed, these results have
already been demonstrated in mice, where high-fat
diets and myostatin inhibition by propeptide overex-
pression prevents reduced insulin sensitivity, elevated
blood glucose and accumulation of fat mass seen in
pair-overfeed wild-type mice (Zhao et al. 2005).
Counter to the above findings, Zimmers et al.
(2002) reported that mice who overexpressed myosta-
tin demonstrated ~40–50% (muscle specific) loss in
muscle mass. Interestingly, mice were hypoglycaemic
as well as demonstrating loss of nearly all fat mass,
despite no noted difference in caloric intake between
overexpressing and wild-type mice. Reduced muscle
mass resulting in hypoglycaemia is an unexpected par-
adox that requires further investigation. This finding
was repeated in vitro in both C2C12 and L6 cell lines,
stimulation of myotubes with myostatin results in a
dose-dependent increase in glucose consumption, with
1.5–2.5 lg myostatin promoting a similar level of glu-
cose consumption (2.5 lmol mL1) as 100 nM insu-
lin. Further, co-incubation with follistatin or the
inhibitory myostatin propeptide blunted heightened
consumption (Chen et al. 2010). One mechanism by
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which myostatin stimulation induces hypoglycaemia is
by increasing mRNA activity of several glucose-regu-
lating proteins, including GLUT1 and GLUT4, IL6,
hexokinase and phosphorylated adenosine triphos-
phate kinase (AMPK; Chen et al. 2010), thereby
increasing cellular glucose uptake. One hypothesis is
that this increase in energy demand is to provide
energy acutely for catabolic processes, as catabolism is
an energy intensive process.
Another potential hypothesis is that myostatin or
some downstream signalling protein may act directly
on metabolic pathways to alter the energy source.
Indeed, it was recently shown that during human mus-
cle atrophy, upregulated pathways were either cell
cycle regulating (including myostatin) or energy
metabolism affecting (Chen et al. 2007). Stimulation
of C2C12 myotubes with myostatin protein results in
increased GLUT1 and GLUT4 mRNA expression and
increases the pAMPK:AMPK ratio (Chen et al. 2010).
Increased GLUT4 mRNA expression and pAMPK
protein levels are also seen in myostatin / mice
(Zhang et al. 2011). Myostatin-stimulated myotubes
show increased glucose consumption, but decreased
total ATP level (Chen et al. 2010), suggesting that the
effects of myostatin on AMPK and glucose are more
likely due to a change in cellular energy state rather
than a direct effect of myostatin on AMPK.
Combined, these results all suggest that a perturba-
tion of myostatin in the whole body, either increasing
or decreasing myostatin activity, results in increased
glucose usage as a metabolic fuel source, resulting in
hypoglycaemia (Fig. 2). From a clinical viewpoint,
myostatin inhibition in the treatment of type II diabe-
tes may present an exciting and useful intervention,
whereby myostatin overexpression to enhance cellular
glucose uptake would not.
Cardiomyocytes homeostasis
Early evidence hinted that myostatin may not solely
act in skeletal muscle. Sharma et al. (1999) identified
the presence of myostatin in heart tissue in both mice
and sheep, by both RT-PCR and immunocytochemis-
try. Indeed, with such structural and metabolic simi-
larities, it is perhaps unsurprising that cardiomyocytes
and myocytes share signalling mechanisms.
Myostatin mRNA levels are elevated in areas sur-
rounding the damage post-infarct, suggesting a role in
regulation of cardiomyocyte apoptosis after hypoxic
injury (Sharma et al. 1999). Plasma myostatin concen-
tration is elevated in non-cachexic human patients
post-heart failure (Gruson et al. 2011). Myostatin-
overexpressing mice also demonstrate cardiac atrophy
with reduced left ventricular mass (Artaza et al.
2007). Indeed, it was recently demonstrated that myo-
statin overexpression results in decreased cardiac
growth in the developing mouse, and this effect
appears to be via inhibition of Akt (Bish et al. 2010),
in a similar manner as myostatin’s inhibition of Akt in
muscle, reviewed above. Excitingly, a recent study
took left ventricle cardiac biopsies from patients with
ischaemic cardiomyopathy and age-matched controls.
The authors showed no difference in myostatin pro-
tein expression from cardiac biopsies between ischae-
mic patients and controls, but did however
demonstrate an increase in circulating myostatin levels
(George et al. 2010). An interesting finding as chronic
heart failure patients have been noted to suffer from
cachexic loss of muscle mass (Anker et al. 1997).
While speculative, it is interesting to hypothesize a
causative role of myostatin increasing systemically
post-heart failure resulting in cachexia in this popula-
tion. If these same signalling mechanisms are main-
tained in the human, then future use of myostatin
inhibitors will need to carefully investigate potential
effects on the heart, as a foreseeable outcome would
be cardiac hypertrophy, clinically problematic.
Outcomes
Myostatin has been well examined in the last decade,
with significant gains in understanding of how it
affects skeletal muscle, and more recently cardiac and
adipose tissue. Smooth muscle appears to be the only
contractile tissue to not express myostatin (Gonzalez-
Cadavid et al. 1998). Research has advanced to the
point where we are now regularly seeing animal stud-
ies of successful myostatin inhibition for the purpose
of muscle hypertrophy (Whittemore et al. 2003,
Figure 2 Conceptual presentation of the myostatin–hypo-
glycaemia paradox. Experimentally induced increases or
decreases in systemic myostatin both result in hypoglycaemia.
Green bars represent homeostasis in terms of blood glucose
(horizontal) and serum myostatin (vertical), with overlap
indicating homeostasis.
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Castillero et al. 2011, Murphy et al. 2011) and are
now attempting in vivo clinical human studies target-
ing myostatin for the prevention of muscle mass loss
in MDX (Wagner et al. 2008). Our understanding of
cachexia and the role of myostatin during cachexic
atrophy continues to evolve; the potential to link myo-
statin inhibitors currently under testing for MDX to
cachexia would enable life prolonging and quality of
life enhancing treatment for a number of terminal
conditions, including cancer, HIV/AIDS, chronic heart
and renal failure and COPD.
Finally, we are beginning to gain an understanding
of the role of myostatin in other tissues, aside from its
primary function in maintaining muscle mass homeo-
stasis. With the ongoing and increasing prevalence of
type II diabetes as a major problem for the world’s
population, any potential paths furthering our under-
standing of glucose homeostasis deserve further atten-
tion. As we have examined above, myostatin appears
to play roles in both the regulation of energy homeo-
stasis and adipose tissue proliferation. The current
work focussing on the development of inhibitors of
myostatin in human muscular dystrophic disorders
could see exciting cross-over in the treatment of diabe-
tes, metabolic syndrome and many other modern
‘Western’ diseases.
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